UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$336M |
| 2 |
AbbVie
ABBV
|
+$235M |
| 3 |
VMW
VMware, Inc
VMW
|
+$163M |
| 4 |
T-Mobile US
TMUS
|
+$156M |
| 5 |
Aptiv
APTV
|
+$154M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$570M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
Apple
AAPL
|
+$394M |
| 4 |
Abbott
ABT
|
+$262M |
| 5 |
Intel
INTC
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.77% |
| 2 | Healthcare | 13.92% |
| 3 | Consumer Discretionary | 13.52% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ENLC
2051
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $540K | ﹤0.01% |
221,108
+5,888
| +3% | +$12.2K |
|
|
CLVS
2052
DELISTED
Clovis Oncology, Inc.
CLVS
| $538K | ﹤0.01% |
+79,755
| New | +$604K |
|
|
CCF
2053
DELISTED
Chase Corporation
CCF
| $538K | ﹤0.01% |
5,247
+2,528
| +93% | +$236K |
|
2054
Vericel Corp
VCEL
$2.31B
| $537K | ﹤0.01% |
38,884
-10,637
| -21% | -$144K |
|
|
PFC
2055
DELISTED
Premier Financial Corp. Common Stock
PFC
| $537K | ﹤0.01% |
30,379
+4,252
| +16% | +$68.8K |
|
2056
LeMaitre Vascular
LMAT
$1.86B
| $535K | ﹤0.01% |
20,252
+9,977
| +97% | +$261K |
|
|
GES
2057
DELISTED
Guess Inc
GES
| $530K | ﹤0.01% |
54,856
-7,499
| -12% | -$66K |
|
|
AGEN
2058
Agenus
AGEN
$290M
| $530K | ﹤0.01% |
6,876
-3,206
| -32% | -$192K |
|
2059
Assembly Biosciences
ASMB
$529M
| $530K | ﹤0.01% |
1,894
+958
| +102% | +$224K |
|
2060
Chord Energy
CHRD
$7.39B
| $529K | ﹤0.01% |
705,411
-1,155,063
| -62% | -$747K |
|
|
TRST
2061
Trustco Bank Corp NY
TRST
$938M
| $529K | ﹤0.01% |
16,699
| – | – |
|
|
ACH
2062
Accendra Health
ACH
$214M
| $526K | ﹤0.01% |
69,092
-1,155
| -2% | -$8.45K |
|
2063
BGC Group
BGC
$4.89B
| $526K | ﹤0.01% |
192,094
-124,452
| -39% | -$345K |
|
2064
Kforce
KFRC
$1.06B
| $526K | ﹤0.01% |
17,994
+7,424
| +70% | +$216K |
|
2065
IMAX
IMAX
$2.66B
| $526K | ﹤0.01% |
46,913
-1,921
| -4% | -$22.5K |
|
2066
National Beverage
FIZZ
$3.01B
| $525K | ﹤0.01% |
17,208
+7,432
| +76% | +$201K |
|
|
GOOD
2067
Gladstone Commercial Corp
GOOD
$627M
| $524K | ﹤0.01% |
27,964
+1,131
| +4% | +$18.5K |
|
2068
Garrett Motion
GTX
$5.57B
| $523K | ﹤0.01% |
94,399
+18,945
| +25% | +$92.5K |
|
|
CIO
2069
DELISTED
City Office REIT
CIO
| $523K | ﹤0.01% |
51,952
+11,895
| +30% | +$110K |
|
2070
E.W. Scripps
SSP
$304M
| $521K | ﹤0.01% |
59,486
-1,736
| -3% | -$13.9K |
|
2071
Viking Therapeutics
VKTX
$4B
| $520K | ﹤0.01% |
72,140
-14,523
| -17% | -$96.4K |
|
2072
Geron
GERN
$949M
| $520K | ﹤0.01% |
238,349
+160,881
| +208% | +$241K |
|
2073
Arcturus Therapeutics
ARCT
$211M
| $519K | ﹤0.01% |
+11,100
| New | +$383K |
|
2074
RE/MAX Holdings
RMAX
$242M
| $518K | ﹤0.01% |
+16,484
| New | +$437K |
|
2075
Calix
CALX
$2.39B
| $517K | ﹤0.01% |
+34,723
| New | +$399K |
|
Similar funds
UBS AM's Q2 2020 Portfolio in Review
As of Q2 2020, UBS AM held 2,605 positions worth $164B, up 18% from $139B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
UBS AM withdrew a net $6.16B in Q2 2020, closing 142 positions and reducing 1,290 holdings. Its most notable exit was Allergan plc, an estimated $203M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, UBS AM opened a new position in Otis Worldwide worth $76.5M.
- UBS AM's largest Q2 2020 buy was Otis Worldwide: 1,345,382 shares worth $76.5M.
- UBS AM added most to NetEase in Q2 2020, an estimated $336M increase.
- UBS AM's biggest Q2 2020 reduction was Alibaba, cutting an estimated $570M.
- UBS AM fully exited Allergan plc in Q2 2020, selling an estimated $203M.
- UBS AM's ten largest holdings make up 24% of its $164B portfolio in Q2 2020.
- UBS AM opened 144 new positions and closed 142 in Q2 2020.
- UBS AM's portfolio value rose 18% quarter-over-quarter to $164B.
Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.